Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc.
Fujirebio Europe today announced the CE marking of the Lumipulse G CK-MB immunoassay, which can be used as an aid in the diagnosis of Acute Myocardial Infarction (AMI) or as a marker of reinfarction. The launch of this assay now completes1 the Lumipulse G Cardiac panel which also includes BNP, high sensitivity Troponin I and Myoglobin.
Fujirebio Europe today announced the CE-marking of the Lumipulse G Total Tau assay for its fully automated LUMIPULSE immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) kit allows for the quantitative determination of total Tau in human cerebrospinal fluid within just 35 minutes.
Fujirebio Europe today announced the release of Lumipulse G HTLV-I/II, a CE-marked CLEIA (chemiluminescent enzyme immunoassay) test kit for in vitro diagnostic use with LUMIPULSE G system for qualitative detection of antibody to HTLV-I and HTLV-II in human serum or plasma for screening of HTLV-I/II viral infection.
Fujirebio Europe has announced the release of the Lumipulse G hs Troponin I assay for use in the diagnosis of Acute Myocardial Infarction (AMI). In addition, the company also launches its Lumipulse G Myoglobin assay, both assays providing precise and sensitive results in 35 minutes.
Fujirebio Europe today announced the release of the Lumipulse G β-Amyloid 1-42 assay for its fully automated LUMIPULSE immunoassay systems. This CE-marked CLEIA (chemiluminescent enzyme immunoassay) kit allows the quantitative measurement of β-amyloid1-42 in human cerebrospinal fluid within just 30 minutes. The Lumipulse G β-Amyloid 1-42 assay is based upon Fujirebio’s well established, pioneering ELISA-based INNOTEST® assay (the first neurodegeneration testing kit launched in 1995) and the know-how of Fujirebio in robust and automated CLEIA testing since the first LUMIPULSE instrument was released in 1992.
Since January 2nd 2017 Fujirebio Diagnostics AB (headquarters in Sweden) and Fujirebio Europe NV (headquarters in Belgium) share the same website, www.fujirebio-europe.com.
Fujirebio Europe today announced the release of Lumipulse G HMW Adiponectin, a biomarker useful in the diagnosis of insulin resistance in obesity and of metabolic syndrome, available on the fully automated LUMIPULSE G series of instruments.
Fujirebio Europe today announced the release of Lumipulse G whole PTH, a 3rd generation assay that is highly useful in the diagnostic of primary hyperparathyroidism, hypoparathyroidism as well as secondary hyperparathyroidism, mainly in nephrology. The Lumipulse G whole PTH is calibrated against the international standard NIBSC WHO 95/646.
Gent, Belgium: July 5th 2016 - Fujirebio Europe has launched a communication campaign under the title "A few drops of insight can lead to an ocean of understanding" intended to help doctors, nurses and healthcare workers explain to patients and their families the advantages of an early diagnosis of Alzheimer's Disease through CSF (Cerebrospinal fluid) testing.